Navigation Links
Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma
Date:12/6/2010

NEW YORK, Dec. 6, 2010 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced data presented for the first time at the 52nd Annual Meeting of the American Society of Hematology showing promising clinical activity, safety and tolerability of perifosine in patients with advanced chronic lymphocytic leukemia (CLL) and Hodgkin's lymphoma (HL).  KRX-0401 (perifosine) is the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway. Key highlights from the two Phase 2 poster presentations are as follows:

Abstract # 2861: "Clinical Activity and Safety of the Combined Therapy with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib In Heavily Pretreated Patients with Relapsed/Refractory Lymphomas: Preliminary Results of a Phase II Trial"  Study Background:  In this Phase 2 study, 26 patients were enrolled with advanced lymphoma (6 NHL, 4 CLL, 1 Waldenstroms and 15 Hodgkin's lymphoma).  73% of patients were previously refractory to their prior therapy, with 85% of patients having had 4 or more prior therapies.  Perifosine (50 mg BID) was started as a single agent for 28 days; After 28 days, patients achieving partial response (PR) or better were continued on single agent perifosine.  Patients achieving less than a PR were given the combination of perifosine (50 mg BID) plus sorafenib (Nexavar®) at 400 mg BID.

Results:  All of the 4 CLL patients in the study achieved a partial response on single-agent perifosine within one month of treatment and remained on perifosine single agent.  Response durations for each of the 4 patients were 4, 8, 9+ and 12 months.  The remaining 22 patients were administered the combination with sorafenib, where 5 of the 15 (33%) Hodgkin's lymphoma patients ac
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients
2. Neuraltus Pharmaceuticals Reports Clinical Results from Phase 1/2 NP002 Study in the Treatment of Dyskinesias Resulting from Levodopa Therapy for Parkinsons Disease
3. Spherix Announces Post-Hoc Analysis of Phase 3 Trial With D-Tagatose in Diabetes
4. Pfizer Announces Positive Phase 3 Trial Results for Axitinib in Patients With Previously-Treated Metastatic Renal Cell Carcinoma (mRCC)
5. Circassia Achieves Major Reduction in Allergic Reactions to House Dust Mite in Phase II Clinical Study of Novel T-cell Vaccine
6. Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting
7. VIDEO from Merck and Co., Inc available on thenewsmarket.com: In Phase III Study Mercks Investigational CETP Inhibitor Anacetrapib Met Safety and Efficacy Endpoints in Patients with CHD
8. Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients
9. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
10. Reata Pharmaceuticals to Present Data from Pivotal Phase 2b Trial in Type 2 Diabetics With Chronic Kidney Disease
11. Pevions Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... WORTH, Texas , Jan. 15, 2014  Humberto C. ... Dermatology Achievement Award" from the Journal of Drugs ... Aesthetic & Clinical Conference (ODAC). The event is January 17-20, ... Florida . The ODAC ...
(Date:1/15/2014)...  In an unprecedented effort to curb the spread of "superbugs" such ... vehicles, an advanced and portable UV germicidal lamp manufactured by MRSA-UV ... In order to prevent EMS paramedics and transport ... West Palm Beach Fire Rescue is the first in ...
(Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... Symphony® CGM System as a non-invasive, wireless continuous glucose ... , Executive Chairman and Interim CEO of Echo Therapeutics, ... Annual Equity Conference. Mr. Doman will ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... Calif., Feb. 9, 2011 The 2007 onset of ... impacted global markets correlated closely with unprecedented numbers of ... and painkiller abuse, according to leading rehabilitation center Cliffside ... for treatment related to those medications, rose over 60 ...
... Rock Creek Pharmaceuticals, a subsidiary of Star Scientific, Inc. ... 4 a provisional patent application was filed with the ... form of a single isomer of anatabine, "S-(-)anatabine". This ... therapeutically effective dose of anatabine to treat chronic low-level ...
Cached Medicine Technology:Treatment for Prescription Drug Addiction and Painkiller Abuse has Risen Sharply Since Onset of Financial Crisis, Reflecting Uncertainty About Economy 2Rock Creek Pharmaceuticals Discloses Filing of Provisional Patent Application For Isolated Anatabine Isomer 2Rock Creek Pharmaceuticals Discloses Filing of Provisional Patent Application For Isolated Anatabine Isomer 3Rock Creek Pharmaceuticals Discloses Filing of Provisional Patent Application For Isolated Anatabine Isomer 4
(Date:4/20/2014)... in children, codeine continues to be prescribed in U.S. ... Children,s Hospital San Francisco. , As reported in the ... provider prescription behaviors to promote the use of better ... "Despite strong evidence against the use of codeine in ... numbers of them each year," said Sunitha Kaiser, MD, ...
(Date:4/18/2014)... group of scientists from the University of Kentucky ... Aging has found interesting new information in a ... disease (PD). , Published in the journal ... cognitive function in depressed and non-depressed patients with ... used to treat motor symptoms of Parkinson,s disease ...
(Date:4/18/2014)... made a discovery that turns 160 years of neuroanatomy ... long known to be essential for the fast transmission ... not as ubiquitous as thought, according to a new ... Stem Cell Institute (HSCI) and the University,s Department of ... Jeff Lichtman, of Harvard,s Department of Molecular and Cellular ...
(Date:4/18/2014)... (Seattle, WA April 18, 2014) Benaroya Research ... to research how blocking a particular molecule in metastatic ... and the number of lung metastases. BRI scientists have ... protein can shrink tumors by 60 - 80 percent ... to the lung. The $1.8 million five-year grant comes ...
(Date:4/18/2014)... . A ... A team led by Ludwik Leibler from the Laboratoire ... Letourneur from the Laboratoire Recherche Vasculaire Translationnelle (INSERM/Universits Paris ... principle of adhesion by aqueous solutions of nanoparticles can ... tissues. This easy-to-use gluing method has been tested on ...
Breaking Medicine News(10 mins):Health News:UCSF study finds codeine often prescribed to children, despite available alternatives 2Health News:Treating depression in PD patients: New research 2Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3
... Centerplate, the hospitality partner to North America,s ... with the Capital Improvement Board (CIB) that its ... Stadium to immediately address all known food safety ... model of operational excellence and exceeds all Health ...
... cancer patients with specific changes in the cancer genome ... after standard treatment compared to patients without these changes, ... 13 in the open-access journal PLoS Genetics . ... steps in the progression of the disease towards an ...
... Minn., Nov. 12 Here are highlights from the ... You may cite this publication as often as you ... attribution is required. Reprinting is allowed for ... editorial policies permit: Visit www.bookstore.mayoclinic.com ...
... GROVE, Wis., Nov. 12 Compirion ... has been awarded contracts with three hospitals nationwide. They ... Regional Hospital in Campbellsville, Kentucky; and Covenant Healthcare in ... improve process efficiencies and financials in the ...
... SCOTTSDALE, Ariz., Nov. 12 Healthcare Trust of America, ... trust, announced the execution of a Purchase and Sale ... located in Spartanburg, South Carolina for approximately $16,250,000. The ... of conditions. , The approximate 108,500 SF Mary Black ...
... Performance Symposium will take place on November 16th at ... Centrale), Milan Central Station. , http://www.mindroom.com/detailinside.php?id=1 ... benefits that the application of Neuroscience Research can bring ... Modern approaches of Neurofeedback and Biofeedback will be discussed ...
Cached Medicine News:Health News:Centerplate and the Capital Improvement Board Investigating Food Safety Violations at Lucas Oil Stadium to Ensure Highest Standards Achieved and Operational Excellence 2Health News:November 2009 Mayo Clinic Women's HealthSource Highlights Reducing Cancer Risk, Tips to Reduce Flatulence and Eating Nuts for Heart Health 2Health News:November 2009 Mayo Clinic Women's HealthSource Highlights Reducing Cancer Risk, Tips to Reduce Flatulence and Eating Nuts for Heart Health 3Health News:November 2009 Mayo Clinic Women's HealthSource Highlights Reducing Cancer Risk, Tips to Reduce Flatulence and Eating Nuts for Heart Health 4Health News:November 2009 Mayo Clinic Women's HealthSource Highlights Reducing Cancer Risk, Tips to Reduce Flatulence and Eating Nuts for Heart Health 5Health News:Compirion Healthcare Solutions Wins Consulting Contracts With Three Hospitals 2Health News:Compirion Healthcare Solutions Wins Consulting Contracts With Three Hospitals 3Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire a 108,500 SF Medical Office Building Located in Spartanburg, South Carolina 2Health News:Peak Performance, Neurofeedback and Biofeedback: New Frontiers of Empowerment From, and In, Sport 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: